This review article discusses the role of BRAF and MEK inhibitors in the treatment of low-grade serous ovarian cancer (LGSOC). BRAF mutations are common in LGSOC and other gynecological cancers, making them a promising target for therapy. While BRAF inhibitors have shown efficacy in BRAF-mutated tumors, resistance is a significant challenge. Combining BRAF and MEK inhibitors has been shown to delay resistance and improve outcomes in preclinical studies. Clinical trials have demonstrated that BRAF/MEK inhibitor combinations are effective in treating LGSOC, with notable responses in patients with BRAF mutations. These combinations have been approved for various cancers, including melanoma, and are being investigated for their potential in gynecological cancers. The article highlights the importance of molecular profiling in identifying patients who may benefit from these therapies and emphasizes the need for further research to optimize treatment strategies for LGSOC. The review also discusses the broader implications of targeting the RAS-RAF-MEK pathway in gynecological cancers, noting the potential for improved outcomes through targeted therapy. Overall, the study underscores the importance of continued research into BRAF and MEK inhibitors as a promising approach for the treatment of LGSOC.This review article discusses the role of BRAF and MEK inhibitors in the treatment of low-grade serous ovarian cancer (LGSOC). BRAF mutations are common in LGSOC and other gynecological cancers, making them a promising target for therapy. While BRAF inhibitors have shown efficacy in BRAF-mutated tumors, resistance is a significant challenge. Combining BRAF and MEK inhibitors has been shown to delay resistance and improve outcomes in preclinical studies. Clinical trials have demonstrated that BRAF/MEK inhibitor combinations are effective in treating LGSOC, with notable responses in patients with BRAF mutations. These combinations have been approved for various cancers, including melanoma, and are being investigated for their potential in gynecological cancers. The article highlights the importance of molecular profiling in identifying patients who may benefit from these therapies and emphasizes the need for further research to optimize treatment strategies for LGSOC. The review also discusses the broader implications of targeting the RAS-RAF-MEK pathway in gynecological cancers, noting the potential for improved outcomes through targeted therapy. Overall, the study underscores the importance of continued research into BRAF and MEK inhibitors as a promising approach for the treatment of LGSOC.